Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to characterize [18F]molecular neuroimaging
(MNI)-1020, a positron emission tomography (PET) radioligand for imaging tau pathology, to
visually and quantitatively assess and compare brain uptake and pharmacokinetics of
[18F]MNI-1020 in participants with probable Alzheimer's disease (AD) and compare with age
matched healthy participants, to evaluate the safety of a single injection of [18F]MNI-1020
and to compare the distribution of tau (using [18F]MNI-1020) and amyloid beta (using
florbetapir) in participants with probable AD.